• Entrepreneur with Investor
    • Science with Business
    • Biotech with Pharma
    • Japan with Taiwan
    • Wealth with Human Health
  • Partners Creator
  • DCI Partners

DCI Partners is a leading venture capital firm focusing on life sciences

 

We have over 20 years' history of investing in biotech start-ups since the period of NIF Ventures.
We are currently managing the largest size of the life science fund in Japan
and playing a key role in supplying funds to promising start-ups.
We aim at increasing the value of our portfolios by providing various hands-on supports
utilizing our team's expertise of clinical development, intellectual property and business development
as well as our extensive network across academics, biotechs and pharmas primarily in Japan and Taiwan.
Beyond classical venture capital firms, we act as a platform
to incubate seeds that have great potential and create new start-ups.

Topics

 

18/11/2024
Satoshi Motomura, Daiwa Corporate Investment's Head of Taipei Representative Office, contributes to Nikkei Biotechnology & Business: "Action-driven and speed-focused: what we can learn from Taiwanese management."
02/07/2024
PRISM BioLab Co.,Ltd., one of our portfolio companies, has been listed on Tokyo Stock Exchange.
10/06/2024
Satoshi Motomura, Daiwa Corporate Investment's Head of Taipei Representative Office, contributes to Nikkei Biotechnology & Business: "Why do Taiwanese startups have such high market caps?"
27/11/2023
Yuka Niimi has been ranked 5th in the "Japan's Venture Capitalist of the Year" by Forbes JAPAN (a Japanese edition of "The Midas List" by Forbes).
17/10/2023
K Pharma, Inc., one of our portfolio companies, has been listed on Tokyo Stock Exchange.
28/06/2023
Noile-Immune Biotech Inc., one of our portfolio companies, has been listed on Tokyo Stock Exchange.
19/01/2023
APRINOIA Therapeutics Inc., one of our portfolio companies, has entered into a definitive agreement for a business combination with Ross Acquisition Corp II, a SPAC founded by Mr. Wilbur Ross who is a prominent investor and the former Commerce Secretary of the United States.
28/12/2022
The founding of a new biotech company「Surv BioPharma Inc.」
22/11/2022
TMS Co., Ltd., one of our portfolio companies, has been listed on Tokyo Stock Exchange.
30/09/2022
The Fund Size increased to JPY 15.3 Billion
30/06/2022
DCI Partners has been adopted as a certified Venture Capital by the Japan Agency for Medical Research and Development (AMED), as a participant of AMED's program to support biotech startups and strengthen the ecosystem.
Visit https://www.amed.go.jp/koubo/19/02/1902C_00003.html for more information.
13/12/2021
The Fund Size increased to JPY 14.5 Billion
24/09/2021
Renascience one of our portfolio companies, has been listed on Tokyo Stock Exchange.
21/12/2020
Establishment of Daiwa Taiwan-Japan BioVenture Investment Limited Partnership II
09/08/2019
StemRIM one of our portfolio companies, has been listed on Tokyo Stock Exchange.
28/06/2019
EirGenix, Inc., one of our portfolio companies, has been listed on Taipei Exchange.
14/02/2019
Open Innovation Partners, Inc., one of our portfolio companies, has obtained FDA approval.
28/01/2019
The founding of a new biotech company「Anexa PEP Inc.」
05/01/2018
A New founded Biotech Company signs an Agreement with Mitsubishi Tanabe Pharma.
01/06/2017
ASLAN Pharmaceuticals Limited, one of our portfolio companies, has been listed on Taipei Exchange.
30/03/2017
The founding of a new biotech company「J-mab Therapeutics, Inc.」
30/07/2015
The Fund Size increased to JPY 11.6 Billion
06/07/2015
DCI Partners will give a speech scheduled on July 22th in Bio Taiwan 2015
Visit http://bio-taiwan.com/en for more information.
12/02/2015
Establishment of Daiwa Taiwan-Japan Biotech Fund Investment Limited Partnership

Corporate Profile

 

Company Name
DCI Partners Co., Ltd.
Head Office

  • GranTokyo North Tower 1-9-1,
    Marunouchi, Chiyoda-ku,Tokyo

    MAP
Establishment
May 20, 2014
Share Capital
50 million yen
Business
Description
Management of venture capital funds specialized in the life science field

[Fund under management]
Daiwa Taiwan-Japan Biotech Fund (Fund I)
Daiwa Taiwan-Japan BioVenture Investment Limited Partnership II (Fund II)
Fund Size
Fund I  : JPY 11.6 Billion
Fund II : JPY 15.3 Billion
Board of
Directors
Hiroki Narita                   President & CEO
Katsumi Uchida              Director
Shuntaro Kodama           Managing Director
Haruyo Takano                Audit & Supervisory Board Member
 

Investment Focus

 

  • Biotech Start-ups centered on the therapeutic field in Japan and Taiwan
  • Spin-out or carve-out opportunities from pharmaceutical / biopharmaceutical companies and academia